Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Proteasomal Degradation Thwarts the Apoptotic Efforts of Bax-Beta Protein

By LabMedica International staff writers
Posted on 27 Jan 2009
A second Bax protein, Bax-beta, has been isolated and characterized as being nearly 100 times more potent as an inducer of apoptosis than the closely related Bax-alpha protein.

Apoptosis or programmed cell death is a complicated process. More...
In healthy cells, the outer membranes of the mitochondria display the apoptosis inhibiting protein Bcl-2. Internal damage to the cell causes a related protein, Bax, to migrate to the surface of the mitochondrion where it inhibits the protective effect of Bcl-2 and inserts itself into the outer mitochondrial membrane. It then pokes holes in the membrane, which allows cytochrome c to leak out. The released cytochrome c binds to the protein Apaf-1 (apoptotic protease activating factor-1). The Apaf-1-cytochrome c complexes aggregate to form apoptosomes that bind to and activate the protease caspase-9. Caspase-9 cleaves and, in so doing, activates other caspases (caspase-3 and -7). The activation of these "executioner" caspases creates an expanding cascade of proteolytic activity, which leads to digestion of structural proteins in the cytoplasm, degradation of chromosomal DNA, and phagocytosis of the cell.

Evidence form RNA data convinced investigators at the Institute of Molecular and Cell Biology (Singapore) that additional and possibly more potent apoptotic proteins should coexist with Bax-alpha. By inhibiting the action of the cell's primary protein digesting organelle, the proteasome, they were able to demonstrate the existence of a second Bax protein, Bax-beta. They reported in the January 16, 2009, issue of the journal Molecular Cell that Bax-beta was normally rapidly degraded and kept at low levels. However, when it was not degraded, it was profoundly apoptotic on its own and worked in concert with Bax-alpha.

"Our research findings reveal that Bax-beta protein levels are normally kept at essentially undetectable levels in healthy cells by the protein degradation machine in cells known as proteasomes," said senior author Dr. Victor C. Yu, an associate professor at the Institute of Molecular and Cell Biology. "This is exciting - if the proteasome-mediated degradation of Bax-beta could be inhibited specifically in cancer cells, it could cause the harmful cancer cells to go through apoptosis."

Related Links:
Institute of Molecular and Cell Biology



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.